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Higher glomerular filtration rate is 
related to insulin resistance but not 
to obesity in a predominantly obese 
non-diabetic cohort
Negar Naderpoor1,2,*, Jasmine G. Lyons3,*, Aya Mousa1, Sanjeeva Ranasinha1, 
Maximilian P. J. de Courten4, Georgia Soldatos1,2 & Barbora de Courten1,2
Glomerular hyperfiltration has been associated with obesity, insulin resistance, and systolic blood 
pressure (SBP). However, previous studies are limited by confounders such as pre-existing diabetes 
or hypertension, or have used indirect measures of adiposity and insulin sensitivity (IS). Therefore, we 
examined the relationship between estimated glomerular filtration rate (eGFR) and IS measured by 
the hyperinsulinaemic euglycaemic clamp in a healthy population on no medications. We performed 
oral glucose tolerance test (OGTT) and measured % body fat (DEXA), BMI, blood pressure and M-value 
(hyperinsulinaemic euglycaemic clamp) in 104 individuals (44 females and 60 males). The majority of the 
study population (n = 89, 85.6%) were classified on their BMI as overweight/obese. eGFR was related to 
age, BMI, M-value (IS), 2-hour glucose levels post OGTT and white blood cell count (WBC) (all p < 0.05); 
but not to SBP (p = 0.1) or fasting glucose levels (p = 0.2). After adjustment for gender, BMI, SBP and 
WBC, the inverse association between eGFR and M-value (p = 0.001), and 2-hour glucose post OGTT 
(p = 0.02) persisted. In conclusion, although eGFR has been associated with BMI and blood pressure 
in previous studies, in our healthy population, eGFR was more closely related to markers of glucose 
metabolism (IS and 2-hour glucose post OGTT) than to BMI and blood pressure.
Glomerular hyperfiltration, which is an abnormally high glomerular filtration rate (GFR), has been reported to 
predict incident diabetes and progression to chronic kidney disease1–3. It is estimated to occur in up to 70% of 
patients with type 1 and 40% of those with type 2 diabetes at the time of diagnosis or in the early stages of disease4. 
Glomerular hyperfiltration is associated with increased risk of albuminuria and faster progression to diabetic 
nephropathy in patients with diabetes1,4,5. Obesity and insulin resistance, two key risk factors for type 2 diabetes, 
have also been associated with hyperfiltration3,6–9. In addition, hypertension, which is common among people 
with obesity and insulin resistance, also increases hyperfiltration1. Therefore, it is not surprising that the pres-
ence of glomerular hyperfiltration has been identified prior to the diagnosis of overt type 2 diabetes2,10. In a large 
community-based population, the prevalence of hyperfiltration increased with increasing fasting plasma glu-
cose levels among those with prediabetes2. The mechanisms underlying hyperfiltration are not fully understood; 
however key processes responsible for altering renal haemodynamics associated with hyperfiltration relate to the 
imbalance of afferent/efferent arteriolar resistance and increased renal blood flow1. Importantly, amelioration of 
glomerular hyperfiltration in type 2 diabetes has been shown to be associated with both improved insulin sen-
sitivity (IS) and a slower decline in renal function over time5. Gender differences have been reported in factors 
affecting insulin resistance as well as renal function and progression to chronic kidney disease11–14. Sex hormones, 
body composition, and fat distribution are possible underlying mechanisms12,14.
To date, observational studies investigating associations between GFR and IS have been very heterogeneous in 
both study population and methodology. They often include patients with comorbid conditions such as obesity, 
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diabetes, hypertension, and different GFR categories, and as such, are unable to separate completely the effect of 
these confounders on renal function15. Furthermore, methods of measuring renal function and IS vary between 
studies and are often not the gold standard. Hence, results may be affected by confounders or may not be gener-
alizable to the wider population. Our study aim was to investigate the relationship between eGFR calculated by 
the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula16, adiposity, and IS measured by 
the gold standard hyperinsulinaemic euglycaemic clamp17 in non-diabetic, normotensive, and drug naive indi-
viduals. Multivariable linear regression models were used to assess these relationships, and to determine other 
significant predictors of eGFR. We also examined gender differences in factors associated with eGFR.
Methods
Participants. Our sample consisted of 104 predominantly obese but otherwise healthy volunteers (44 female 
and 60 male) from the community in Melbourne, aged 18 to 57 years (median ± interquartile range 29 ± 14) who 
underwent a rigorous protocol employing measures of obesity, adiposity, and insulin sensitivity. Participants 
were part of our ongoing studies investigating risk factors for cardiometabolic diseases in healthy individuals. 
Being overweight/obese based on BMI was an inclusion criterion for one of these studies. Phone screening using 
a standard questionnaire was conducted initially for each volunteer to ensure that they did not have any co-mor-
bidities, did not take any medications or illicit drugs, and did not smoke. Specifically, participants were screened 
at their first visit to ensure they were non-diabetic according to an oral glucose tolerance test (OGTT) [World 
Health Organization (WHO) 2006 criteria18], and had a normal physical examination and routine blood analyses. 
The protocol was approved by the Alfred Hospital and Monash University Ethics Committees and complied with 
the Declaration of Helsinki 2004. All subjects provided written informed consent prior to participation.
Participants were characterized for anthropometric measures, body composition, glucose tolerance, insu-
lin sensitivity, blood pressure, white blood cell count, and glomerular filtration rate assessed as estimated GFR 
(eGFR).
Research design and measurements. All subjects underwent screening, which involved a medical his-
tory, physical examination including blood pressure measurement, and basic laboratory tests including fasting 
plasma lipid levels, liver function tests, urea, creatinine, eGFR, and electrolytes. Those who were found healthy 
underwent anthropometric assessments, an OGTT, and a hyperinsulinaemic euglycaemic clamp. Prior to met-
abolic testing, participants were asked to abstain from strenuous exercise and caffeine for at least 24 hours. All 
metabolic testing was performed after a 12-h overnight fast.
Anthropometric measurements. Body weight and waist and hip circumferences were measured and 
waist-to-hip ratio (WHR = waist (cm)/hip (cm)) was calculated as an index of body fat distribution. Body compo-
sition was assessed by total body dual-energy X-ray absorptiometry (DEXA) (Lunar Radiation Corp., Madison, 
WI, USA). Body mass index (BMI) was calculated as [weight (kg)/height2 (m2)]. BMI categories were defined as 
lean = BMI < 25 kg/m2, overweight = BMI of 25–29.99 kg/m2, obese = BMI ≥ 30 kg/m2.
Metabolic studies. Average systolic and diastolic blood pressure (SBP, DBP) was derived for each partici-
pant from three measurements using an automated sphygmomanometer (M6 Automatic BP monitor, Omron, 
Japan) after at least 5 minutes rest. Mean arterial pressure was calculated as 2 × DBP + SBP/3. A two-hour 75-g 
OGTT was performed after a 12-h overnight fast and glucose tolerance status was determined by WHO criteria18. 
Plasma glucose concentrations were determined by the glucose oxidase method (ELM 105 Radiometer and YSI 
2300 Stat Glucose Analyser).
Insulin sensitivity was measured during a hyperinsulinemic-euglycemic clamp, performed as per our pub-
lished protocol19. In brief, after an overnight fast, we collected baseline blood and tested plasma glucose levels at 
0 minute, after which the clamp was initiated by an intravenous bolus injection of insulin (9 mU/kg). A continu-
ous intravenous insulin infusion was then administered for at least 120 minutes at a constant rate of 40 mU per m2 
body surface area per minute. Plasma glucose was measured every 5 minutes during the clamp and the variable 
infusion rate of glucose was adjusted to maintain blood glucose at a constant value of about 5 mmol/L. This infu-
sion achieved steady state plasma insulin concentrations and the rate of total insulin-stimulated glucose disposal 
(M-value) was calculated for the last 30 min of the insulin infusion. We defined insulin resistance as M < 4.7 mg/
kg/min20. Blood samples collected at baseline were used for analysis of WBC and creatinine. Glomerular filtration 
rate was estimated by use of the CKD-Epidemiology Collaboration (CKD-EPI) equation16.
Statistical analysis. Statistical analyses were conducted using STATA (version 14). Participant characteris-
tics in total, and according to gender, are presented as means ± standard deviation (SD), or medians [interquartile 
range], with differences analysed by independent Student’s t-tests for continuous and normally distributed var-
iables, and Mann-Whitney U tests for non-normally distributed variables. Normality of distribution was tested 
using the Shapiro-Wilk test and inspection of frequency histograms. Chi-square test was used to investigate if a 
significant difference existed in the distribution of BMI categories (lean, overweight, obese) between genders. 
Pearson correlation (r) was used as a measure of the strength of correlations between each variable and eGFR. 
Multivariable linear regression analysis was used to assess the association between eGFR as the dependent varia-
ble with IS (M) as an independent variable, and to determine the effect of other covariates. We initially plotted the 
relationship between eGFR and IS and confirmed a linear trend. For multivariable regression models, we adjusted 
for variables which were significantly correlated to eGFR based on Pearson correlation and those known to asso-
ciate with eGFR based on previous studies including systolic blood pressure. A two-tailed p-value < 0.05 was 
considered statistically significant. One-way ANOVA followed by post hoc Tukey test was applied to examine the 
mean eGFR across BMI categories among the insulin sensitive individuals, and also between insulin sensitive and 
insulin resistant obese individuals. We also examined the difference in mean eGFR across tertiles of IS and 2-hour 
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glucose post OGTT using one-way ANOVA. For IS, tertile 1 was defined as M between 1.24 and 5.69 mg/kg/min 
(mean ± SD: 4.05 ± 1.0, N = 35), tertile 2 as M between 5.86 and 8.83 mg/kg/min (7.5 ± 0.9, N = 35) and tertile 3 
as M between 8.84 to 17.41 mg/kg/min (11.8 ± 2.7, N = 34). For 2-hour glucose post OGTT, tertile 1 was defined 
as glucose level between 2.5 and 4.6 mmol/L (mean ± SD: 3.9 ± 0.5, N = 35), tertile 2 as glucose level between 4.6 
and 5.8 mmol/L (5.2 ± 0.4, N = 35) and tertile 3 as glucose level between 5.9 and 10.6 mmol/L (7.0 ± 1.2, N = 34). 
We conducted trend analyses to further investigate the relationships between eGFR and IS, and 2-hour glucose 
post OGTT. Post hoc, we tested for interactions running the Wald test in the adjusted model and performed sec-
ondary multivariable analyses where we found a significant interaction.
Results
Participant characteristics are presented in Table 1. The majority of the study population (n = 89, 85.6%) were 
classified overweight or obese according to the WHO BMI classification21 (38.5% overweight and 47.1% obese). 
Twenty-seven participants (26%) were insulin resistant (M < 4.7 mg/kg/min) (Table 2). Males had higher mean 
systolic blood pressure (SBP), arterial pressure, fasting plasma glucose level, fat free mass (FFM) and serum cre-
atinine level and a higher median waist-to-hip-ratio (WHR) compared to females (Table 1). Females had higher 
mean percent body fat compared to males. However, there were no significant differences in BMI and IS between 
genders (Table 1). Males also had a less favorable lipid profile with higher mean total cholesterol and triglycerides, 
and lower mean high-density lipoprotein cholesterol (HDL-C) levels (Table 1). In univariable analysis, eGFR was 
negatively related to age (Table 3). Serum creatinine levels were not different across BMI categories (p = 0.4) and 
between insulin resistant and insulin sensitive groups (p = 0.08).
Relationship between eGFR and anthropometric measures. There was a positive association 
between eGFR and BMI (r = 0.23, p = 0.02), and waist circumference (r = 0.23, p = 0.02) but eGFR was not 
Variable All participants Male (n = 60, 57.7%) Female (n = 44, 42.3%) P
*Age (year) 29.00 [14] 29.00 [14] 28.00 [18] 0.8
Anthropometric
*BMI (Kg/m2) 29.56 [6.1] 29.14 [7.6] 30.15 [5.1] 0.6
Percent body fat 36.09 ± 10.4 31.18 ± 9.0 42.96 ± 8.1 < 0.001
Fat free mass (kg) 54.64 ± 12.7 62.27 ± 10.6 43.98 ± 5.7 < 0.001
*Waist-to-hip ratio 0.91 [0.1] 0.96 [0.1] 0.89 [0.1] < 0.001
*Waist circumference (cm) 99.25 [17] 100.75 [16] 96.50 [17] 0.08
Metabolic 
Fasting plasma glucose level 
(mmol/L) 4.64 ± 0.5 4.76 ± 0.5 4.49 ± 0.5 0.01
2-hour glucose postOGTT (mmol/L) 5.36 ± 1.5 5.20 ± 1.4 5.56 ± 1.6 0.2
M (mg/kg/min) 7.74 ± 3.6 7.31 ± 3.1 8.33 ± 4.1 0.2
Creatinine (μ mol/L) 68.58 ± 14.0 75.68 ± 10.73 58.19 ± 11.7 < 0.001
eGFR (mL/min/1.73 m2) 114.26 ± 14.4 116.12 ± 13.1 111.73 ± 15.8 0.1
Systolic blood pressure (mmHg) 119.99 ± 12.6 123.45 ± 12.5 115.28 ± 11.2 0.001
Diastolic blood pressure (mmHg) 77.46 ± 9.5 78.14 ± 9.8 76.53 ± 9.2 0.3
Mean arterial pressure (mmHg) 91.64 ± 9.6 93.24 ± 9.8 89.45 ± 9.0 0.04
Total cholesterol (mmol/L) 4.64 ± 0.8 4.79 ± 0.9 4.45 ± 0.7 0.03
*Triglyceride (mmol/L) 1.14 [0.8] 1.40 [1.2] 1.00 [0.6] < 0.001
HDL-C (mmol/L) 1.22 ± 0.3 1.15 ± 0.3 1.31 ± 0.3 0.008
LDL-C (mmol/L) 2.84 ± 0.7 2.93 ± 0.8 2.70 ± 0.6 0.1
Inflammatory marker
*White blood cell count (x109/L) 6.05 [2.1] 6.10 [2.3] 6.00 [2.0] 0.9
Table 1.  Anthropometric and metabolic profile. *Not normally distributed variable. Data presented as 




(M ≥ 4.7 mg/kg/min)
Insulin resistant 
(M < 4.7 mg/kg/min) Total
Lean (BMI < 25) 15 0 15
Overweight (BMI 25 to 29.99) 35 6 41
Obese (BMI ≥ 30) 27 21 48
Total 77 27 104
Table 2.  Insulin sensitivity based on BMI category.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:45522 | DOI: 10.1038/srep45522
associated with percent body fat (r = 0.1, p = 0.3), fat free mass (r = 0.11 p = 0.3) and WHR (r = 0.1, p = 0.3). 
None of the anthropometric measures were independently related to eGFR after additional adjustment for IS 
(all p > 0.05). There was a trend for BMI, particularly in the overweight group, interacting on the relationship 
between eGFR and IS (Fig. 1). However, this interaction did not reach statistical significance (p = 0.07). Using 
post-hoc Tukey test, when categorized based on IS, there was no significant difference in the mean eGFR between 
lean, overweight, and obese individuals within insulin sensitive (M ≥ 4.7 mg/kg/min) (p = 0.3) and insulin resist-
ant (M < 4.7 mg/kg/min) groups (p = 0.4).
Relationship between eGFR, blood pressure, and lipid profile. eGFR was not associated with sys-
tolic (r = 0.15, p = 0.1), diastolic (r = 0.14, p = 0.1), or mean arterial blood pressure (r = 0.16, p = 0.1). These 
associations remained non-significant after adjustment for adiposity ( p > 0.1). Regarding lipid profile, eGFR 
was related to HDL-C (r = − 0.2, p = 0.04), but not related to total cholesterol (r = − 0.05, p = 0.6), LDL-C 
(r = − 0.03, p = 0.7) and triglyceride levels (r = 0.14, p = 0.2). After adjusting for adiposity, no relationships were 
found between eGFR and any of the plasma lipid measures (all p > 0.2).
eGFR and white blood cell count. eGFR was associated with white blood cell count (WBC) (r = 0.21, 
p = 0.04), but not after adjustment for adiposity (p > 0.1).
Relationship between eGFR, glycaemic indices and insulin sensitivity. eGFR was positively related 
to 2-hour glucose post OGTT (r = 0.24, p = 0.01), and inversely related to IS (M) (r = − 0.42, p < 0.001) but not 
related to fasting glucose (r = 0.13, p = 0.2). In addition, we found significant differences in eGFRs across tertiles 
of IS measured as M (122.94 ± 11.4 mL/min/1.73 m2 in the least insulin sensitive group vs 110.26 ± 12.4 mL/
min/1.73 m2 in the moderately sensitive group vs 109.44 ± 15.3 mL/min/1.73 m2 in the most insulin sensitive 
group; p < 0.0001). Similarly, there were significant differences in eGFRs across tertiles of 2-hour glucose post 
OGTT (120.74 ± 13.3 mL/min/1.73 m2 in the first tertile with the highest 2-hour glucose vs 111.69 ± 14.8 mL/
min/1.73 m2 in the second tertile vs 110.54 ± 13.2 mL/min/1.73 m2 in the third tertile with the lowest 2-hour 
glucose). In the multivariable analysis, the relationship between eGFR and IS remained significant after additional 
adjustments for, BMI, SBP, and WBC (Table 3). Similarly, the relationship between eGFR and 2-hour glucose 
post OGTT remained significant after additional adjustments for BMI, SBP, and WBC (p < 0.01). When both 
IS and 2-hour glucose post OGTT were in the model adjusted for BMI and SBP, IS was the only significant 
predictor of eGFR (p = 0.009). Use of waist circumference, WHR, fat free mass, or percent body fat instead of 
BMI yielded similar results regarding the association between eGFR and IS (p < 0.05). However, further analysis 
Variable
Univariable Multivariable
β (95% CI) p β (95% CI) p
BMI 0.6 (0.1 to 1.1) 0.02 − 0.1 (− 0.7 to 0.5) 0.7
SBP 0.2 (− 0.1 to 0.4) 0.1 0.1 (− 0.06 to 0.3) 0.2
WBC 1.70 (0.1 to 3.3) 0.04 0.5 (− 1.1 to 2.1) 0.6
Insulin Sensitivity (M) − 1.7 (− 2.4 to − 1.0) <0.001 − 1.5 (− 2.5 to − 0.6) 0.002
2-hour glucose post OGTT 0.2 (0.5 to 4.1) 0.01 0.9 (− 1.0 to 2.7) 0.4
Table 3.  Multiple regression analysis of eGFR (dependent variable) and insulin sensitivity (independent 
variable) after adjustment for covariates. eGFR: estimated glomerular filtration rate; BMI: Body mass index; 
β : unstandardized coefficient, CI: confidence interval, M: insulin sensitivity; p: p-value; SBP: systolic blood 
pressure; WBC: white blood cell count.
Figure 1. Association of eGFR and insulin sensitivity (M) by BMI. 
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revealed a significant interaction by gender on the relationship between eGFR and IS (p = 0.02). Hence, univar-
iable and multivariable linear regression analyses were conducted separately in males and females (Tables 4 and 
5, respectively). We used model 1 to assess the relationship between eGFR and IS (M) adjusting for potential 
confounders including BMI, SBP and WBC. In model 2, we adjusted for model 1 covariates as well as 2-hour 
glucose post OGTT. Using post hoc Tukey test, among obese individuals (BMI ≥ 30), there was a significant dif-
ference in mean eGFR between insulin sensitive (M ≥ 4.7 mg/kg/min) and insulin resistant (M < 4.7 mg/kg/min) 
groups (p = 0.0001). When divided by gender, we found a significant relationship between eGFR and IS in females 
(adjusted R2 = 0.38, p = 0.005), but not in males (adjusted R2 = 0.29, p = 0.9) (Tables 4 and 5; Fig. 2). Among 
males, 2-hour glucose post OGTT was related to eGFR in the regression analysis (Table 4). Replacing BMI with 
percent body fat, fat free mass, waist circumference or WHR in separate regression models by gender did not alter 
these associations (data not shown).
Discussion
Our study shows that in a predominantly obese but otherwise healthy population of adults, there is a modest 
positive relationship between measures of adiposity and eGFR, and a strong negative relationship between IS and 
eGFR, which is independent of adiposity and SBP. Furthermore, our findings suggest a gender difference exists in 
the relationship between eGFR and IS. In females, IS was the strongest predictor of eGFR. In men, eGFR was most 
strongly associated with 2-hour glucose post OGTT, which is a marker of both IS and β cell function22.
In our study, measures of adiposity (BMI, waist circumference, and percent body fat) were positively related 
to eGFR after adjustment for age and gender. However, after additional adjustment for IS, IS but not adiposity 
was related to eGFR. Aligned with this, we showed no significant difference in mean eGFR across BMI categories 
when participants were classified by M-value as insulin sensitive or resistant. This suggests that insulin resistance, 
rather than obesity, may be the key driver in the development of glomerular hyperfiltration, which has been 
shown to be an early predictor of albuminuria, chronic renal disease and renal failure4,5,23. Several studies have 
reported an association between measures of adiposity, and glomerular hyperfiltration. A progressive increase 
in GFR has been observed with increasing BMI even in non-obese healthy individuals9. BMI has been shown 
to directly affect renal haemodynamics and alter the afferent/efferent balance, which could result in glomeru-
lar hypertension and hyperfiltration and ultimately, renal injury9,23. However, the relationship between eGFR 
and BMI is often not adjusted for insulin resistance9,24–26. Furthermore, obesity is associated with hypertension, 
insulin resistance, and dyslipidaemia, all of which are known risk factors for renal disease and it is difficult to dif-
ferentiate the independent contribution of each of these factors to renal hyperfiltration. There are other studies, 
however, which have reported reduced GFR and reduced renal plasma flow associated with increased BMI, and 
especially with central obesity27. A greater WHR and increased intra-abdominal pressure due to visceral fat in 
obese individuals have been found to be associated with renal vein compression, and diminished venous outflow 
from the renal veins due to increased inferior vena cava pressure6,8. These could result in slower renal blood flow 




Model 1 Model 2
β (95% CI) p β (95% CI) p β (95% CI) p
BMI 0.1 (− 0.6 to 0.7) 0.8 − 0.4 (− 1.2 to 0.5) 0.4 − 0.3 (− 1.1 to 0.5) 0.5
SBP 0.1 (− 0.1 to 0.4) 0.3 0.2 (− 0.1 to 0.4) 0.3 0.2 (− 0.1 to 0.4) 0.3
WBC 0.7 (− 1.3 to 2.7) 0.5 0.2 (− 1.9 to 2.4) 0.8 − 0.5 (− 2.7 to 1.6) 0.6
Insulin sensitivity (M) − 0.7 (− 1.8 to 0.4) 0.2 − 0.9 (− 2.4 to 0.5) 0.2 − 0.2 (− 1.7 to 1.3) 0.8
2-hour glucose post OGTT 3.4 (1.2 to 5.7) 0.004 3.6 (0.8 to 6.4) 0.01
Table 4.  Multiple regression analysis of eGFR and insulin sensitivity in males. Model 1: Adjusted for BMI, 





Model 1 Model 2
β (95% CI) p β (95% CI) p β (95% CI) p
Β Μ Ι 1.3 (0.5 τ ο 2.1) 0.003 0.4 (− 0.4 tο 1.3) 0.3 0.4 (− 0.4 tο 1.3) 0.3
SBP 0.1 (− 0.4 τ ο 0.5) 0.7 0.1 (− 0.2 tο 0.5) 0.3 0.1 (− 0.3 tο 0.5) 0.5
WBC 3.0 (0.5 to 5.6) 0.02 1.3 (− 1.1 to 3.6) 0.3 1.2 (− 1.2 to 3.6) 0.3
Insulin sensitivity (M) − 2.4 (− 3.3 to − 1.4) 0.000 − 1.8 (− 3.1 to − 0.6) 0.003 − 1.9 (− 3.2 to − 0.6) 0.005
2-hour glucose post OGTT 1.5 (− 1.5 to 4.6) 0.3 − 0.3 (− 2.9 to 2.3) 0.8
Table 5.  Multiple regression analysis of eGFR and insulin sensitivity in females. Model 1: Adjusted for BMI, 
SBP, WBC, insulin sensitivity(M). Model 2: Adjusted for BMI, SBP, WBC, insulin sensitivity(M), 2-hour glucose 
post OGTT.
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Our results are consistent with another cross-sectional study of 1,572 young, healthy men which showed that 
insulin resistance based on homeostatic model assessment (HOMA-IR) was higher in men with hyperfiltration 
compared to those without hyperfiltration3. GFR in this study was calculated using the Cockcroft–Gault equation. 
Other studies described either no relationship or a positive relationship between GFR and insulin sensitivity. A 
study of 574 non-diabetic individuals found no relationship between CKD-EPI-calculated eGFR and insulin 
resistance quantified by an insulin suppression test28. The study population was older compared to our study 
(mean age of 50 years among those without metabolic syndrome and 53 years among those with metabolic syn-
drome, compared to 31.2 years in our study), with expectedly lower mean eGFR compared to our study sample 
(89.3 mL/min/1.73 m2 among those without metabolic syndrome and 87.5 mL/min/1.73 m2 among those with 
metabolic syndrome vs 114.3 mL/min/1.73 m2 in our study). Another study of 864 non-diabetic participants, 
calculated GFR based on the Modification of Diet in Renal Disease (MDRD) equation, and IS by the frequently 
sampled intravenous glucose tolerance test using mathematical modeling methods to measure IS index29. This 
study also found no association between IS index and GFR. Apart from the limitations of GFR based on MDRD16, 
the studied population were again much older than ours (mean age 52.6 ± 1.0). Notably, some of the partici-
pants in both studies were on antihypertensive medications (angiotensin-converting-enzyme inhibitors (ACEI) 
or angiotensin receptor blockers) or statins, which could have confounded their results28,29. Among previous 
cross-sectional studies that have reported a positive association between IS and GFR, only one used the hyperin-
sulinaemic euglycaemic clamp technique to measure IS7. This study included exclusively elderly men (mean age 
71 ± 0.59 years). As expected, even in the subgroup with normal renal function, the mean GFR was much lower 
than the mean GFR in our study (65.3 ± 10.4 vs 114.3 ± 14.4 ml/min/1.73 m2) and the majority had hypertension 
(> 66%), dyslipidaemia (> 85%), or both, with some requiring medications. Therefore, these results are not gen-
eralizable to young and/or healthy populations7. In young, healthy cohorts as in our study, renal changes initiated 
by insulin resistance are more likely to manifest as increased GFR, whereas in older individuals with features of 
metabolic syndrome, the effect of insulin resistance on kidney function is likely to result in decreased GFR. In 
addition, antihypertensive therapy is an important confounder in the above study owing to its protective effects 
on kidneys. Other cross-sectional studies that showed a positive association between IS and GFR used surrogate 
markers, including fasting insulin and HOMA-IR to evaluate IS and involved older populations with lower mean 
GFR or established renal disease, with comorbidities such as hypertension and dyslipidaemia, and, in one study, 
with diabetes30–33.
The pathophysiological mechanisms underlying our observations are likely complex and we suggest that 
these are primarily associated with hyperinsulinaemia secondary to insulin resistance. Hyperinsulinaemia has 
been shown in animal and human experimental studies to induce renal afferent vasodilatation, increase frac-
tional sodium reabsorption, activate the renin-angiotensin system, and increase GFR34–38. Insulin also promotes 
the production of insulin-like growth factor that has been shown to increase renal plasma flow and GFR39,40. 
Moreover, impaired IS and compensatory hyperinsulinaemia is associated with increased sympathetic nervous 
system activity, increased adipocytokines such as IL-6, TNF-α , leptin, and resistin leading to increased chronic 
low-grade inflammation and endothelial dysfunction8,41. A combination of these factors can lead to altered renal 
haemodynamics that may eventually lead to glomerular hyperfiltration. Glomerular hyperfiltration can then 
increase vascular permeability resulting in albuminuria41. Notably, glomerular hyperfiltration has been shown 
to improve after interventions such as sodium restriction and weight reduction42,43. This may have important 
clinical implications as appropriate screening and implementing early interventions to improve IS may reverse 
hyperfiltration and prevent progression to albuminuria and further renal injury, particularly in those at high risk 
of impaired IS who may not necessarily be overweight or obese.
To our knowledge, no previous study has investigated gender differences in metabolic predictors of eGFR in 
relatively young non-diabetic adults. Sex hormones and different patterns of fat distribution between males and 
females may play a role in the development of glomerular hyperfiltration and likely interact with other factors 
affecting renal function. Gender differences in renal haemodynamic function, renal response to glycaemia and 
ACEIs, and patterns of microalbuminuria have been reported in animal and human studies12,13,44. Men have been 
Figure 2. Association of eGFR and insulin sensitivity (M) by gender. 
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reported to have a higher risk of developing chronic kidney disease and a faster progression to end-stage renal 
disease14,45. Our data suggests that insulin resistance may increase glomerular hyperfiltration in females, whereas 
in males, hyperfiltration develops only after glucose intolerance occurs and perhaps contributes to a more rapid 
decline in renal function with the further deterioration of glucose tolerance. This hypothesis needs to be tested in 
prospective and intervention studies.
Our small sample size and the predominance of overweight and obese individuals in our study sample lim-
its the generalizability of our findings. Additionally, directionality and causality of the observed relationships 
cannot be ascertained in these cross-sectional analyses. We did not use inulin clearance measurement, which 
is considered the gold-standard method of determining renal function46. Calculated GFR may also underesti-
mate true GFR in normal and high-to-normal ranges, especially in obese populations, although the CKD-EPI 
formula appears to be more accurate than the other commonly used equation- MDRD16. Moreover, not mon-
itoring sodium and protein intake in participants’ diets and the absence of urinary measures of renal function 
including 24-hour urinary sodium, does not allow for comprehensive assessment of other factors that might 
have affected eGFR in our study. Further studies investigating renal hemodynamics such as intra-renal sodium 
loading, renin-angiotensin system activation, and tubular glomerular feedback, in addition to renal injury mark-
ers, such as kidney injury molecule-1, liver fatty acid binding protein, and interleukin-1847, would add to our 
understanding of the mechanisms of hyperfiltration in the context of insulin resistance. Finally, we did not find 
any association between eGFR and SBP. This is likely due to the narrow range of blood pressure in our popula-
tion as all participants had normal blood pressure levels. However, to the best of our knowledge, this is the first 
study examining the relationship between eGFR, adiposity, and IS based on the hyperinsulinaemic euglycaemic 
clamp in a predominantly obese but otherwise healthy cohort and investigating gender differences in predictors 
of eGFR. We were also able to adjust for adiposity based on percent body fat from DEXA which, to our knowl-
edge, has not been previously reported.
We advance the knowledge in this field by demonstrating that higher eGFR was more closely related to insulin 
resistance than to obesity. In addition, we show gender differences in predictors of eGFR. Gender-specific anal-
yses revealed IS as the main predictor of eGFR in women; whereas 2-hour glucose post OGTT was particularly 
important in men. Our findings suggest that impaired IS, via increasing glomerular filtration rate and potentially 
hyperfiltration, may play an independent role in the pathophysiology of renal injury, particularly in females. 
Given the limitations of this cross-sectional study, randomised clinical trials are needed to establish causality and 
to examine the effect of improving insulin sensitivity in reversing glomerular hyperfiltration and preventing renal 
impairment.
References
1. Palatini, P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrology, dialysis, 
transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 27, 1708–1714, 
doi: 10.1093/ndt/gfs037 (2012).
2. Okada, R. et al. Glomerular hyperfiltration in prediabetes and prehypertension. Nephrology, dialysis, transplantation: official 
publication of the European Dialysis and Transplant Association - European Renal Association 27, 1821–1825, doi: 10.1093/ndt/gfr651 
(2012).
3. Tomaszewski, M. et al. Glomerular hyperfiltration: A new marker of metabolic risk. Kidney Int 71, 816–821 (2007).
4. Helal, I., Fick-Brosnahan, G. M., Reed-Gitomer, B. & Schrier, R. W. Glomerular hyperfiltration: definitions, mechanisms and clinical 
implications. Nature reviews. Nephrology 8, 293–300, doi: 10.1038/nrneph.2012.19 (2012).
5. Ruggenenti, P. et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 35, 2061–2068, doi: 
10.2337/dc11-2189 (2012).
6. Scaglione, R. et al. Central obesity and hypertension: pathophysiologic role of renal haemodynamics and function. International 
journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity 19, 403–409 (1995).
7. Nerpin, E. et al. Insulin Sensitivity Measured With Euglycemic Clamp Is Independently Associated With Glomerular Filtration Rate 
in a Community-Based Cohort. Diabetes Care 31, 1550–1555, doi: 10.2337/dc08-0369 (2008).
8. Wahba, I. M. & Mak, R. H. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clinical 
journal of the American Society of Nephrology: CJASN 2, 550–562, doi: 10.2215/cjn.04071206 (2007).
9. Bosma, R. J., van der Heide, J. J., Oosterop, E. J., de Jong, P. E. & Navis, G. Body mass index is associated with altered renal 
hemodynamics in non-obese healthy subjects. Kidney Int 65, 259–265, doi: 10.1111/j.1523-1755.2004.00351.x (2004).
10. Melsom, T. et al. Impaired fasting glucose is associated with renal hyperfiltration in the general population. Diabetes Care 34, 
1546–1551, doi: 10.2337/dc11-0235 (2011).
11. Lichnovska, R., Gwozdziewiczova, S. & Hrebicek, J. Gender differences in factors influencing insulin resistance in elderly 
hyperlipemic non-diabetic subjects. Cardiovasc Diabetol 1, 4 (2002).
12. Sakurai, M. et al. Sex Differences in Associations Among Obesity, Metabolic Abnormalities, and Chronic Kidney Disease in Japanese 
Men and Women. Journal of Epidemiology advpub, doi: 10.2188/jea.JE20150208 (2016).
13. Cherney, D. Z., Sochett, E. B. & Miller, J. A. Gender differences in renal responses to hyperglycemia and angiotensin-converting 
enzyme inhibition in diabetes. Kidney Int 68, 1722–1728, doi: 10.1111/j.1523-1755.2005.00588.x (2005).
14. Gretz, N., Zeier, M., Geberth, S., Strauch, M. & Ritz, E. Is gender a determinant for evolution of renal failure? A study in autosomal 
dominant polycystic kidney disease. American journal of kidney diseases: the official journal of the National Kidney Foundation 14, 
178–183 (1989).
15. Jerums, G., Premaratne, E., Panagiotopoulos, S. & MacIsaac, R. J. The clinical significance of hyperfiltration in diabetes. Diabetologia 
53, 2093–2104, doi: 10.1007/s00125-010-1794-9 (2010).
16. Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine 150, 604–612 (2009).
17. DeFronzo, R. A., Tobin, J. D. & Andres, R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. The 
American journal of physiology 237, E214–223 (1979).
18. WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia, report of a WHO/IDF consultation, Geneva. 
(2006).
19. de Courten, B. et al. Vitamin D supplementation for the prevention of type 2 diabetes in overweight adults: study protocol for a 
randomized controlled trial. Trials 16, 335, doi: 10.1186/s13063-015-0851-6 (2015).
20. Bergman, R. N., Finegood, D. T. & Ader, M. Assessment of insulin sensitivity in vivo. Endocr Rev 6, 45–86, doi: 10.1210/edrv-6-1-45 
(1985).
www.nature.com/scientificreports/
8Scientific RepoRts | 7:45522 | DOI: 10.1038/srep45522
21. WHO. Global database on body mass index- BMI classification (2004) (Date of access:05/02/2017) doi: http://apps.who.int/bmi/
index.jsp?introPage= intro_3.html.
22. Manco, M. et al. One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose 
tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes 
Care 33, 2090–2097, doi: 10.2337/dc09-2261 (2010).
23. Kwakernaak, A. J., Toering, T. J. & Navis, G. Body mass index and body fat distribution as renal risk factors: a focus on the role of 
renal haemodynamics. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association 
- European Renal Association 28 Suppl 4, iv42-49, doi: 10.1093/ndt/gft331 (2013).
24. Chagnac, A. et al. Glomerular hemodynamics in severe obesity. American Journal of Physiology - Renal Physiology 278, F817–F822 
(2000).
25. Gelber, R. P. et al. Association between body mass index and CKD in apparently healthy men. American journal of kidney diseases: 
the official journal of the National Kidney Foundation 46, 871–880, doi: 10.1053/j.ajkd.2005.08.015 (2005).
26. Ejerblad, E. et al. Obesity and risk for chronic renal failure. Journal of the American Society of Nephrology: JASN 17, 1695–1702, doi: 
10.1681/asn.2005060638 (2006).
27. Pinto-Sietsma, S. J. et al. A central body fat distribution is related to renal function impairment, even in lean subjects. American 
journal of kidney diseases: the official journal of the National Kidney Foundation 41, 733–741 (2003).
28. Johns, B. R., Pao, A. C. & Kim, S. H. Metabolic syndrome, insulin resistance and kidney function in non-diabetic individuals. 
Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal 
Association 27, 1410–1415, doi: 10.1093/ndt/gfr498 (2012).
29. Lorenzo, C. et al. Risk of type 2 diabetes among individuals with high and low glomerular filtration rates. Diabetologia 52, 
1290–1297, doi: 10.1007/s00125-009-1361-4 (2009).
30. Kubo, M. et al. Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study. Kidney Int 55, 
2450–2456, doi: 10.1046/j.1523-1755.1999.00458.x (1999).
31. Onat, A. et al. Association between mild renal dysfunction and insulin resistance or metabolic syndrome in a random nondiabetic 
population sample. Kidney & blood pressure research 30, 88–96, doi: 10.1159/000100487 (2007).
32. Chen, J. et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. Journal of the American Society of 
Nephrology 14, 469–477, doi: 10.1097/01.ASN.0000046029.53933.09 (2003).
33. Fragoso, A., Mendes, F., Silva, A. P. & Neves, P. L. Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal 
disease. Journal of Diabetes and its Complications, doi: 10.1016/j.jdiacomp.2015.05.010 (2015).
34. Cohen, A. J., McCarthy, D. M. & Stoff, J. S. Direct hemodynamic effect of insulin in the isolated perfused kidney. The American 
journal of physiology 257, F580–585 (1989).
35. Tucker, B. J., Anderson, C. M., Thies, R. S., Collins, R. C. & Blantz, R. C. Glomerular hemodynamic alterations during acute 
hyperinsulinemia in normal and diabetic rats. Kidney Int 42, 1160–1168 (1992).
36. Dengel, D. R., Goldberg, A. P., Mayuga, R. S., Kairis, G. M. & Weir, M. R. Insulin resistance, elevated glomerular filtration fraction, 
and renal injury. Hypertension 28, 127–132 (1996).
37. Skott, P. et al. Effects of insulin on kidney function and sodium excretion in healthy subjects. Diabetologia 32, 694–699 (1989).
38. Sarafidis, P. A. & Ruilope, L. M. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. American 
journal of nephrology 26, 232–244, doi: 10.1159/000093632 (2006).
39. Baumann, U., Eisenhauer, T. & Hartmann, H. Increase of glomerular filtration rate and renal plasma flow by insulin-like growth 
factor-I during euglycaemic clamping in anaesthetized rats. European journal of clinical investigation 22, 204–209 (1992).
40. Guler, H. P., Eckardt, K. U., Zapf, J., Bauer, C. & Froesch, E. R. Insulin-like growth factor I increase glomerular filtration rate and 
renal plasma flow in man. Acta endocrinologica 121, 101–106 (1989).
41. De Cosmo, S., Menzaghi, C., Prudente, S. & Trischitta, V. Role of insulin resistance in kidney dysfunction: Insights into the 
mechanism and epidemiological evidence. Nephrology Dialysis Transplantation 28, 29–36, doi: 10.1093/ndt/gfs290 (2013).
42. Bank, N., Lahorra, G., Aynedjian, H. S. & Wilkes, B. M. Sodium restriction corrects hyperfiltration of diabetes. The American journal 
of physiology 254, F668–676 (1988).
43. Ezequiel, D. G., Costa, M. B., Chaoubah, A. & de Paula, R. B. Weight loss improves renal hemodynamics in patients with metabolic 
syndrome. Jornal brasileiro de nefrologia: orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia 34, 36–42 (2012).
44. Coonrod, B. A. et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications 
Study. Diabetes Care 16, 1376–1383 (1993).
45. Hopper, J. Jr., Trew, P. A. & Biava, C. G. Membranous nephropathy: its relative benignity in women. Nephron 29, 18–24 (1981).
46. Jones, G. R. D. & Lim, E.-M. The National Kidney Foundation Guideline on Estimation of the Glomerular Filtration Rate. The 
Clinical Biochemist Reviews 24, 95–98 (2003).
47. de Geus, H. R. H., Betjes, M. G. & Bakker, J. Biomarkers for the prediction of acute kidney injury: a narrative review on current 
status and future challenges. Clinical Kidney Journal 5, 102–108, doi: 10.1093/ckj/sfs008 (2012).
Acknowledgements
We wish to thank all volunteers for their participation in the study. Barbora de Courten is supported by Royal 
Australasian College of Physicians, National Health and Medical Research Council of Australia and a Future 
Leader Fellowship (100864) from the National Heart Foundation. Negar Naderpoor and Aya Mousa are recipients 
of Australian Postgraduate Award scholarships.
Author Contributions
N.N.- contributed to data collection, conducted analyses of data, prepared the final draft of the manuscript. J.L.- 
conducted the initial data analysis, wrote the first draft of the manuscript, and critically reviewed the final draft. 
A.M. and G.S.- contributed to data collection and critically reviewed the manuscript. S.R.- contributed to the 
analyses of data and critically reviewed the manuscript. M.d.C.- received funding for the study and critically 
reviewed the manuscript. B.d.C.- received funding for the study, contributed to data collection, critically reviewed 
the manuscript.
Additional Information
Competing Interests: The authors declare no competing financial interests.
How to cite this article: Naderpoor, N. et al. Higher glomerular filtration rate is related to insulin resistance but 
not to obesity in a predominantly obese non-diabetic cohort. Sci. Rep. 7, 45522; doi: 10.1038/srep45522 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
9Scientific RepoRts | 7:45522 | DOI: 10.1038/srep45522
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2017
